Randomized controlled trials (RCTs) have demonstrated that use of real-time continuous glucose monitoring (rtCGM) reduces HbA1c levels and confers other glycemic benefits in individuals with T2D treated with intensive insulin regimens.4–6 Although intermittent and short-term rtCGM use in T2D patients who are treated with less intensive therapies has also shown similar benefits,7–10 the clinical efficacy of routine rtCGM use in this population has not been well studied. The gene discussed is INS; the disease is type 2 diabetes mellitus.